Burst mitofusin activation reverses neuromuscular dysfunction in murine CMT2A
- Washington University School of Medicine, United States
- Mossakowski Medical Research Centre, Poland
- Cedars-Sinai Medical Center, United States
- Carver College of Medicine, University of Iowa, United States
Abstract
Charcot-Marie-Tooth disease type 2A (CMT2A) is an untreatable childhood peripheral neuropathy caused by mutations of the mitochondrial fusion protein, mitofusin (MFN) 2. Here, pharmacological activation of endogenous normal mitofusins overcame dominant inhibitory effects of CMT2A mutants in reprogrammed human patient motor neurons, reversing hallmark mitochondrial stasis and fragmentation independent of causal MFN2 mutation. In mice expressing human MFN2 T105M, intermittent mitofusin activation with a small molecule, MiM111, normalized CMT2A neuromuscular dysfunction, reversed pre-treatment axon and skeletal myocyte atrophy, and enhanced axon regrowth by increasing mitochondrial transport within peripheral axons and promoting in vivo mitochondrial localization to neuromuscular junctional synapses. MiM111-treated MFN2 T105M mouse neurons exhibited accelerated primary outgrowth and greater post-axotomy regrowth, linked to enhanced mitochondrial motility. MiM111 is the first pre-clinical candidate for CMT2A.
Data availability
All data generated or analyzed during this study are included in the manuscript.
Article and author information
Author details
Funding
NIH (R35HL135736)
- Gerald W Dorn II
NIH (R41NS113642)
- Gerald W Dorn II
NIH (R41NS115184)
- Gerald W Dorn II
Muscular Dystrophy Association (628906)
- Gerald W Dorn II
McDonnell Center for Cellular and Molecular (Neurobiology Postdoctoral Fellowship)
- Antonietta Franco
Harrington Discovery Institute (Scholar-Innovator awardee)
- Gerald W Dorn II
The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.
Ethics
Animal experimentation: All experimental procedures were approved by Washington University in St. Louis School of Medicine Animal Studies Committee; IACUC protocol number 19-0910, Exp:12/16/2022 (Gerald Dorn, PI).
Copyright
© 2020, Franco et al.
This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.
Metrics
-
- 4,210
- views
-
- 537
- downloads
-
- 43
- citations
Views, downloads and citations are aggregated across all versions of this paper published by eLife.
Citations by DOI
-
- 43
- citations for umbrella DOI https://doi.org/10.7554/eLife.61119
Download links
A two-part list of links to download the article, or parts of the article, in various formats.
Downloads (link to download the article as PDF)
Open citations (links to open the citations from this article in various online reference manager services)
Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)
Burst mitofusin activation reverses neuromuscular dysfunction in murine CMT2A
eLife 9:e61119.
https://doi.org/10.7554/eLife.61119
